Presentation is loading. Please wait.

Presentation is loading. Please wait.

James K. Kirklin, MD, Francis D. Pagani, MD, PhD, Robert L

Published byWesley Richard Modified over 6 years ago

Similar presentations

Presentation on theme: "James K. Kirklin, MD, Francis D. Pagani, MD, PhD, Robert L"— Presentation transcript:

1 Eighth annual INTERMACS report: Special focus on framing the impact of adverse events 
James K. Kirklin, MD, Francis D. Pagani, MD, PhD, Robert L. Kormos, MD, Lynne W. Stevenson, MD, Elizabeth D. Blume, MD, Susan L. Myers, BBA, QMIS, Marissa A. Miller, DVM, MPH, J. Timothy Baldwin, PhD, James B. Young, MD, David C. Naftel, PhD  The Journal of Heart and Lung Transplantation  Volume 36, Issue 10, Pages (October 2017) DOI: /j.healun Copyright © 2017 International Society for the Heart and Lung Transplantation Terms and Conditions

2 Figure 1 Summary of INTERMACS implants between June 2006 and December VAD, ventricular assist device; R, right; L, left; TAH, total artificial heart. The Journal of Heart and Lung Transplantation  , DOI: ( /j.healun ) Copyright © 2017 International Society for the Heart and Lung Transplantation Terms and Conditions

3 Figure 2 Parametric survival curve and associated hazard function for continuous flow implants including both isolated left ventricular assist devices (LVADs) and biventricular support (BiVAD). The dashed lines indicate 70% confidence limits. The Journal of Heart and Lung Transplantation  , DOI: ( /j.healun ) Copyright © 2017 International Society for the Heart and Lung Transplantation Terms and Conditions

4 Figure 3 Kaplan-Meier survival following continuous flow ventricular assist device implant, stratified by era at the time of implant. LVAD, left ventricular assist device; BiVAD, biventricular assist device. *One patient was implanted with a continuous flow device before 2008 and was excluded from this depiction. The Journal of Heart and Lung Transplantation  , DOI: ( /j.healun ) Copyright © 2017 International Society for the Heart and Lung Transplantation Terms and Conditions

5 Figure 4 Actuarial survival stratified by whether the ventricular assist device implant represented the original operation, the second operation (first pump replacement), or the third operation (second pump replacement). LVAD, left ventricular assist device; BiVAD, biventricular assist device. Depiction is as in Figure 3. The Journal of Heart and Lung Transplantation  , DOI: ( /j.healun ) Copyright © 2017 International Society for the Heart and Lung Transplantation Terms and Conditions

6 Figure 5 Competing outcomes depiction for continuous flow left ventricular assist devices (CFLVADs) in patients who are listed for heart transplantation (bridge-to-transplant [BTT]). At any point in time, the sum of the proportions for each outcome equals 1. The Journal of Heart and Lung Transplantation  , DOI: ( /j.healun ) Copyright © 2017 International Society for the Heart and Lung Transplantation Terms and Conditions

7 Figure 6 Hazard function curves indicating instantaneous risk of death over time for the major causes/modes of death. LVAD, left ventricular assist device; BiVAD, biventricular assist device; RHF, right heart failure; MSOF, multiple system organ failure. The Journal of Heart and Lung Transplantation  , DOI: ( /j.healun ) Copyright © 2017 International Society for the Heart and Lung Transplantation Terms and Conditions

8 Figure 7 Cumulative hazard function for major causes/modes of death. LVAD, left ventricular assist device; BiVAD, biventricular assist device; RHF, right heart failure; MSOF, multiple system organ failure. The Journal of Heart and Lung Transplantation  , DOI: ( /j.healun ) Copyright © 2017 International Society for the Heart and Lung Transplantation Terms and Conditions

9 Figure 8 Kaplan-Meier survival curves, stratified by INTERMACS profile at the time of implant. Depiction is as in Figure 3. LVAD, left ventricular assist device; BiVAD, biventricular assist device. The Journal of Heart and Lung Transplantation  , DOI: ( /j.healun ) Copyright © 2017 International Society for the Heart and Lung Transplantation Terms and Conditions

10 Figure 9 Kaplan-Meier survival curves, stratified by device strategy and era. Depiction is as in Figure 3. LVAD, left ventricular assist device; BiVAD, biventricular assist device. The Journal of Heart and Lung Transplantation  , DOI: ( /j.healun ) Copyright © 2017 International Society for the Heart and Lung Transplantation Terms and Conditions

11 Figure 10 Kaplan-Meier survival curves, stratified by era and biventricular support (CFBiVAD) vs total artificial heart (TAH). The Journal of Heart and Lung Transplantation  , DOI: ( /j.healun ) Copyright © 2017 International Society for the Heart and Lung Transplantation Terms and Conditions

12 Figure 11 Freedom from severe right heart failure (RHF) (Kaplan-Meier), stratified by INTERMACS profile at implant. RVAD, right ventricular assist device; LVAD, left ventricular assist device; BiVAD, biventricular assist device. The Journal of Heart and Lung Transplantation  , DOI: ( /j.healun ) Copyright © 2017 International Society for the Heart and Lung Transplantation Terms and Conditions

13 Figure 12 Freedom from pump-related infection (PRI), stratified by INTERMACS profile. The depiction is as in Figure 11. CF-LVAD, continuous flow left ventricular assist device; BiVAD, biventricular assist device. The Journal of Heart and Lung Transplantation  , DOI: ( /j.healun ) Copyright © 2017 International Society for the Heart and Lung Transplantation Terms and Conditions

14 Figure 13 Freedom from first stroke, stratified by INTERMACS profile. The depiction is as in Figure 11. CF-LVAD, continuous flow left ventricular assist device; BiVAD, biventricular assist device. The Journal of Heart and Lung Transplantation  , DOI: ( /j.healun ) Copyright © 2017 International Society for the Heart and Lung Transplantation Terms and Conditions

15 Figure 14 Freedom from first readmission, stratified by INTERMACS profile. The depiction is as in Figure 11. CF-LVAD, continuous flow left ventricular assist device; BiVAD, biventricular assist device. The Journal of Heart and Lung Transplantation  , DOI: ( /j.healun ) Copyright © 2017 International Society for the Heart and Lung Transplantation Terms and Conditions

16 Figure 15 Freedom from the combined major event of first infection, bleeding, device malfunction, stroke, or death. The depiction is as in Figure 11. CF-LVAD, continuous flow left ventricular assist device; BiVAD, biventricular assist device. The Journal of Heart and Lung Transplantation  , DOI: ( /j.healun ) Copyright © 2017 International Society for the Heart and Lung Transplantation Terms and Conditions

17 Figure 16 Solution to the multivariable equation for risk of death after 3 months, conditional on 3-month survival. The dashed lines indicate the 70% confidence limits. LVAD, left ventricular assist device; BiVAD, biventricular assist device. The Journal of Heart and Lung Transplantation  , DOI: ( /j.healun ) Copyright © 2017 International Society for the Heart and Lung Transplantation Terms and Conditions

Download ppt "James K. Kirklin, MD, Francis D. Pagani, MD, PhD, Robert L"

Similar presentations

Are we ready to implant LVAD’s in the less sick? Ileana L. Piña, MD, MPH Professor of Medicine and Epi/Pop Health Albert Einstein College of Medicine Associate.

Are we ready to implant LVAD’s in the less sick? Ileana L. Piña, MD, MPH Professor of Medicine and Epi/Pop Health Albert Einstein College of Medicine Associate.
Predicting Major Outcomes after MCSD Implant 1 Risk Factors for Death, Transplant, and Recovery James Kirklin, MD David Naftel, PhD.

Predicting Major Outcomes after MCSD Implant 1 Risk Factors for Death, Transplant, and Recovery James Kirklin, MD David Naftel, PhD.
Predicting Major Outcomes after MCSD Implant 1 Risk Factors for Death, Transplant, and Recovery James Kirklin, MD David Naftel, PhD.

Predicting Major Outcomes after MCSD Implant 1 Risk Factors for Death, Transplant, and Recovery James Kirklin, MD David Naftel, PhD.
HeartWare HVAD: Risk Factors for Adverse Outcomes Mark S. Slaughter, MD Professor and Chair Department Cardiovascular and Thoracic Surgery University of.

HeartWare HVAD: Risk Factors for Adverse Outcomes Mark S. Slaughter, MD Professor and Chair Department Cardiovascular and Thoracic Surgery University of.
INTERMACS: June 2006 – December 2012: CMS Report Adults: n=7849 All primary implants as of 12/31/2012 n= 7928 Pediatric patients: n=79 (patients < 19 yrs.

INTERMACS: June 2006 – December 2012: CMS Report Adults: n=7849 All primary implants as of 12/31/2012 n= 7928 Pediatric patients: n=79 (patients < 19 yrs.
Comparative cost-effectiveness of the HeartWare versus HeartMate II left ventricular assist devices used in the United Kingdom National Health Service.

Comparative cost-effectiveness of the HeartWare versus HeartMate II left ventricular assist devices used in the United Kingdom National Health Service.
Systolic blood pressure on discharge after left ventricular assist device insertion is associated with subsequent stroke Michael E. Nassif, MD, Anjan Tibrewala,

Systolic blood pressure on discharge after left ventricular assist device insertion is associated with subsequent stroke Michael E. Nassif, MD, Anjan Tibrewala,
Sixth INTERMACS annual report: A 10,000-patient database James K. Kirklin, MD, David C. Naftel, PhD, Francis D. Pagani, MD, PhD, Robert L. Kormos, MD,

Sixth INTERMACS annual report: A 10,000-patient database James K. Kirklin, MD, David C. Naftel, PhD, Francis D. Pagani, MD, PhD, Robert L. Kormos, MD,
Janet T. Lee, MD, Rosemary F. Kelly, MD, Marshall I

Janet T. Lee, MD, Rosemary F. Kelly, MD, Marshall I
The Registry of the International Society for Heart and Lung Transplantation: Thirty- second Official Adult Lung and Heart-Lung Transplantation Report—2015;

The Registry of the International Society for Heart and Lung Transplantation: Thirty- second Official Adult Lung and Heart-Lung Transplantation Report—2015;
Patterns and Predictors of Physical Functional Disability at 5 to 10 Years After Heart Transplantation  Kathleen L. Grady, PhD, RN, David C. Naftel, PhD,

Patterns and Predictors of Physical Functional Disability at 5 to 10 Years After Heart Transplantation  Kathleen L. Grady, PhD, RN, David C. Naftel, PhD,
Identifying patients for advanced heart failure therapy by screening patients with cardiac resynchronization therapy or implantable cardioverter-defibrillator:

Identifying patients for advanced heart failure therapy by screening patients with cardiac resynchronization therapy or implantable cardioverter-defibrillator:
Impact of aortic valve closure on adverse events and outcomes with the HeartWare ventricular assist device  David Dobarro, MD, Marian Urban, MD, Karen.

Impact of aortic valve closure on adverse events and outcomes with the HeartWare ventricular assist device  David Dobarro, MD, Marian Urban, MD, Karen.
Incremental and independent value of cardiopulmonary exercise test measures and the Seattle Heart Failure Model for prediction of risk in patients with.

Incremental and independent value of cardiopulmonary exercise test measures and the Seattle Heart Failure Model for prediction of risk in patients with.
Can the Seattle Heart Failure Model Be Used to Risk-stratify Heart Failure Patients for Potential Left Ventricular Assist Device Therapy?  Wayne C. Levy,

Can the Seattle Heart Failure Model Be Used to Risk-stratify Heart Failure Patients for Potential Left Ventricular Assist Device Therapy?  Wayne C. Levy,
Jennifer A. Cowger, MD, Matthew A

Jennifer A. Cowger, MD, Matthew A
The Registry of the International Society for Heart and Lung Transplantation: Twenty- seventh official adult heart transplant report—2010  Josef Stehlik,

The Registry of the International Society for Heart and Lung Transplantation: Twenty- seventh official adult heart transplant report—2010  Josef Stehlik,
Impact of initial Norwood shunt type on young hypoplastic left heart syndrome patients listed for heart transplant: A multi-institutional study  Waldemar.

Impact of initial Norwood shunt type on young hypoplastic left heart syndrome patients listed for heart transplant: A multi-institutional study  Waldemar.
Pre-operative mortality risk assessment in patients with continuous-flow left ventricular assist devices: Application of the HeartMate II risk score 

Pre-operative mortality risk assessment in patients with continuous-flow left ventricular assist devices: Application of the HeartMate II risk score 
The Registry of the International Society for Heart and Lung Transplantation: Thirty-first Official Adult Heart Transplant Report—2014; Focus Theme: Retransplantation 

The Registry of the International Society for Heart and Lung Transplantation: Thirty-first Official Adult Heart Transplant Report—2014; Focus Theme: Retransplantation 

Similar presentations

Ads by Google